AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
AbbVie's EPS for the twelve months ending Jun 30, 2026 was $3.54, up 68.6% year over year. For fiscal 2025 it was $2.36, down 1.3% from the year before. Over ten years it grew -2.8% a year on average. The highest annual figure on record is $6.63 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.36 | -1.3% |
| FY2024 | Dec 31, 2024 | $2.39 | -12.1% |
| FY2023 | Dec 31, 2023 | $2.72 | -59.0% |
| FY2022 | Dec 31, 2022 | $6.63 | +2.8% |
| FY2021 | Dec 31, 2021 | $6.45 | +137.1% |
| FY2020 | Dec 31, 2020 | $2.72 | -48.5% |
| FY2019 | Dec 31, 2019 | $5.28 | +44.3% |
| FY2018 | Dec 31, 2018 | $3.66 | +10.9% |
| FY2017 | Dec 31, 2017 | $3.30 | -9.1% |
| FY2016 | Dec 31, 2016 | $3.63 | +16.0% |
| FY2015 | Dec 31, 2015 | $3.13 | +184.5% |
| FY2014 | Dec 31, 2014 | $1.10 | -57.0% |
| FY2013 | Dec 31, 2013 | $2.56 | -23.6% |
| FY2012 | Dec 31, 2012 | $3.35 | +53.7% |
| FY2011 | Dec 31, 2011 | $2.18 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.03 | +290.4% |
| Q1 FY2026 | Mar 31, 2026 | $0.39 | -45.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.02 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.10 | -88.6% |
| Q2 FY2025 | Jun 30, 2025 | $0.52 | -32.5% |
| Q1 FY2025 | Mar 31, 2025 | $0.72 | -6.5% |
| Q4 FY2024 | Dec 31, 2024 | -$0.02 | -104.3% |
| Q3 FY2024 | Sep 30, 2024 | $0.88 | -12.0% |
| Q2 FY2024 | Jun 30, 2024 | $0.77 | -32.5% |
| Q1 FY2024 | Mar 31, 2024 | $0.77 | +492.3% |
| Q4 FY2023 | Dec 31, 2023 | $0.46 | -66.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.00 | -54.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.14 | +123.5% |
| Q1 FY2023 | Mar 31, 2023 | $0.13 | -94.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.38 | -38.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.21 | +24.2% |
| Q2 FY2022 | Jun 30, 2022 | $0.51 | +21.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.51 | +26.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.26 | +22500.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.78 | +38.0% |
| Q2 FY2021 | Jun 30, 2021 | $0.42 | – |
| Q1 FY2021 | Mar 31, 2021 | $1.99 | -1.5% |
| Q4 FY2020 | Dec 31, 2020 | $0.01 | -99.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.29 | +2.4% |
| Q2 FY2020 | Jun 30, 2020 | -$0.46 | -193.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.02 | +22.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.88 | – |
| Q3 FY2019 | Sep 30, 2019 | $1.26 | -30.4% |
| Q2 FY2019 | Jun 30, 2019 | $0.49 | -61.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.65 | -5.2% |
| Q4 FY2018 | Dec 31, 2018 | -$1.23 | -4200.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.81 | +79.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.26 | +5.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.74 | +64.2% |
| Q4 FY2017 | Dec 31, 2017 | $0.03 | -96.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.01 | +4.1% |
| Q2 FY2017 | Jun 30, 2017 | $1.19 | – |
| Q1 FY2017 | Mar 31, 2017 | $1.06 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.85 | – |
| Q3 FY2016 | Sep 30, 2016 | $0.97 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?